About Us
Medibiofarma is a Spanish clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases.
Mission
The discovery and development of novel, small molecule drugs
- for the treatment of cancer, specifically through activation of the immune system.
- for the treatment of non-cancer, target-related diseases.
Vision
To make disease-modifying treatments available to patients with serious or life-threatening conditions
How do we achieve our vision
At Medibiofarma, we are:
- The Drug Discovery Process
- Virtual Drug Design
- Medicinal Chemistry
- Intellectual Property
- Project Management
- Business Development
- Raising Funds
All other activities for full characterization and development of compounds into clinical candidates, are carried out through established partnerships with contract research organizations, research centers and universities.
Leading scientists
Rodolfo Rodríguez Iglesias
Founder, IP director & General Manager
Rodolfo Rodríguez Iglesias is Chemical Engineer, Master in Science in Biotechnological Processes and Patent Technician. He has 15 years of experience in industrial property and 8 years as a specialist in vaccine production. With knowledge in the protection of inventions and strategies for the registration of intellectual property, drafting of patents, patent research, patentability studies, infringement studies, freedom to operate, procedures for processing and examining national and European patents, and international applications of patents, and in the biotechnological sector in fermentation, molecular biology, basic immunology, etc.
Since December 2016, he is founder and IP responsable in Medibiofarma.
Richard Roberts, PhD
Chief Scientific Officer
Richard holds a degree in Natural Sciences and a PhD in Organic Chemistry from the University of Cambridge, followed by a three-year post-doc at Imperial College, London.
He has 20 years’ experience in the field of medicinal chemistry and drug discovery. After a spell as Team Leader at Syngenta, UK, he moved to Almirall in Barcelona in 2002 as a Senior Medicinal Chemist. From 2008 he was Program Leader, discovering potent molecules related to asthma, cough and itch. He was also involved in a range of other activities, from open innovation and compound logistics to managing major collaborations.
Since 2016 he has been in the biotech sector, first as Director of Drug Discovery at Minoryx, a clinical-stage company focused on rare genetic disorders. He was then Director of Medicinal Chemistry at the Kærtor Foundation, a pioneer incubator for early drug discovery in collaboration with industry.
He joined Medibiofarma as Chief Scientific Officer in 2020